Gepatit C virusi tanadagi bir qator zararlanishlarni keltirib chiqaradi,
shu jumladan jigarni ham zararlaydi. Ushbu maqolada lipid metabolizmining
buzilishi deb ataladigan virusli gepatit C bilan zararlanganlarda uchraydigan
muammolardan biri muhokama qilinadi. Tadqiqotning asosiy mazmuni qonning
lipidlar spektri (umumiyxolesterin (xolesterin), yuqori zichlikda gilipoproteinlar
(HDL), juda past zichlikdagilipoproteinlar (VLDL), triglitseridlar (TG)) niqonning
biokimyoviy tekshiruvlari bilan aniqlash orqali tahlil qilishdir. Surunkali gepatit C
bilan og'rigan bemorlarda xolesterolning ko'payishi va uning aterogen
subfraktsiyalari ko'rinishidagi lipid metabolizmining umumiy buzilishi abdominal
semizlikka olib keladi.
Hepatitis C virus causes a number of lesions in the body, including
the liver itself. This article addresses one of the problems encountered in viral
hepatitis C, the so-called lipid metabolism disorder. The main content of the study
is the analysis of determining the levels of the lipid spectrum (total cholesterol
(cholesterol), high density lipoproteins (HDL), very low density lipoproteins
(VLDL), triglycerides (TG)) of the blood, by biochemical blood tests. Common
lipid metabolism disorders in the form of an increase in cholesterol and its
atherogenicsubfractions in patients with chronic hepatitis C leads to an abdominal
obesity.
| № | Muallifning F.I.Sh. | Lavozimi | Tashkilot nomi |
|---|---|---|---|
| 1 | Xikmatullayeva A.S. | ||
| 2 | Boqiyeva S.R. | ||
| 3 | Saydivaliyeva K.S. |
| № | Havola nomi |
|---|---|
| 1 | 1. Бацков С.С. Гастроэнтерология и гепатология.Учебное пособие/ С.С. Бацков,А.Н. Беляев, А.В. Гордиенко и др. – СПб: Политехника сервис, 2014.–260 с. 2. Гейвандова Н.И., Ягода А.В., Гурницкая М.В., Первушин Ю.В. Вирус-ассоциированные нарушения липидного обмена при хроническом гепатите С. Клиническая гепатология. 2007, 3(4): 25-28; 3. Семендяева М.Е. Неалкогольная жировая болезнь печени как медицинская и социальная проблема. Клиническая практика. 2012, 2: С.71-80; 4. Ascione A., Tartaglione T., Di Costanzo G.G. Natural history of chronic hepatitis C virus infection. Dig. Liver Dis. 2007; 39(Suppl. 1): 4–7; 5. Chung W.J. Chronic hepatitis C and insulin resistance Korean J. Gastroenterol. 2012; 59(4): 268-274; 6. Cobbold J.F., Cox I.J., Brown A.S. et al. Lipidprofilingofpre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. Hepatol. Res. 2012; 42(7): 714-720; 7. Daniel J.F., Mohamed L.H., Mathieu L., et al. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. Viruses. 2013; 5: 1292-1324; 8. Hwang S.J., Lee S.D. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J. Gastroenterol. Hepatol. 2011; 26(Suppl 1): 96-101; 9. Moucari R., Asselah T., Cazals-Hatem D. et al .Insulinresistancein chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008; 134: 416-423; 10. Patton H.M., Patel K., Behling C. et al. Theimpactofsteatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004; 40: 484-490; 11. Perlemuter G., Sabile A., Letteron P. et al. Hepatitis C viruscore protein inhibits microsomal triglyceride transfer activity and very low density lipoprotein secretion: a model of viral’ related steatosis. Fed. Amer. Soc. Exp. Biol. J. 2002; 16: 185–194. |